The full results of a clinical trial for the Pfizer-BioNTech Covid-19 vaccine were published in the New England Journal of Medicine on Thursday, a major milestone that came as a committee of the US Food and Drug Administration met to discuss its approval.
For more coronavirus news, visit our dedicated page.
An editorial related to the scientific paper said: “The trial results are impressive enough to hold up in any conceivable analysis. This is a triumph.”
The full trial included almost 44,000 volunteers, several thousand more than the number seen in prior analyses. Around half received the vaccine and the rest a placebo.
The paper confirmed that a two-dose regimen of BNT162b2 was 95 percent effective in preventing Covid-19 infection.
Coronavirus: Saudi Arabia approves Pfizer-BioNTech COVID-19 vaccine for use
Coronavirus: UK COVID-19 Pfizer vaccine allergic reactions explained
Coronavirus: Hackers steal Pfizer/BioNTech COVID-19 vaccine data, companies say
The vaccine worked similarly across “age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions,” the paper said.
Among 10 cases of severe Covid-19 after the first dose, nine occurred in placebo recipients and one in a person who received the vaccine.
The editorial that accompanied the study did flag certain “minor issues.”
“The number of severe cases of Covid-19 (one in the vaccine group and nine in the placebo group) is too small to draw any conclusions about whether the rare cases that occur in vaccinated persons are actually more severe,” it said.
Other questions include whether unexpected safety issues may arise when the number of people vaccinated grows to millions and possibly billions of people.
Also unknown is whether more side effects will emerge with longer follow-up, how long the vaccine remains effective, whether it will limit transmission, and how it will work in children, pregnant women, and immuno-compromised patients.
Coronavirus: UK COVID-19 Pfizer vaccine allergic reactions explainedBritain's medicines regulator has advised people with a history of significant allergies not to get the Pfizer-BioNTech COVID-19 vaccine after two ... Coronavirus
Coronavirus: Hackers steal Pfizer/BioNTech COVID-19 vaccine data, companies sayUS drugmaker Pfizer and its German partner BioNTech said on Wednesday that documents related to their development of a COVID-19 vaccine had been ... Coronavirus
Coronavirus: Canada approves Pfizer-BioNTech COVID-19 vaccineCanada on Wednesday approved its first COVID-19 vaccine, clearing the way for doses of the Pfizer Inc and BioNTech SE shots to be delivered and ... World News
Coronavirus: UK warns people with serious allergies to avoid Pfizer vaccineBritain’s medicine regulator has advised that people with a history of significant allergic reactions do not get Pfizer-BioNTech’s COVID-19 vaccine ... Coronavirus
Coronavirus: Israel to receive initial shipment of Pfizer vaccineIsrael will receive an initial shipment of Pfizer Inc coronavirus vaccines on Wednesday, Prime Minister Benjamin Netanyahu’s office said, a day ... Coronavirus
CDC advisers to review data on Pfizer-BioNTech COVID-19 vaccineA US Centers for Disease Control and Prevention (CDC) advisory panel will meet on Friday to review data on the COVID-19 vaccine developed by Pfizer ... Coronavirus
Coronavirus: Saudi Arabia approves Pfizer-BioNTech COVID-19 vaccine for useSaudi Arabia’s Food and Drug Authority announced on Thursday that it has approved registration of the Pfizer-BioNTech coronavirus vaccine in the ... Coronavirus